A post-AAD 2024 discussion on the importance of tailoring acne and rosacea management to individual patients’ needs, focusing more attention on diverse skin types and backgrounds.
DocTalk
Our latest podcast offering is an in-depth dive into ophthalmology hosted by Dr. Sheth, featuring conversations with experts on the latest research, conference news, and daily practice.
Lawrence Eichenfield, MD, reviews major drug approvals and advancement of screening and prevention strategies for the youngest patients with atopic dermatitis.
As 2022 concludes, a dermatologist reflects on the first drug approved for vitiligo.
A post-AAO 2022 discussion on avacincaptad pegol in GA and what this groundbreaking treatment represents in filling a currently unmet need.
President and CSO of Odylia Therapeutics discusses the gene therapy pipeline, research and differences in operating as a nonprofit biotech company.
There are several early phase trials underway for new hepatitis B virus treatments.
Dr. David Rosmarin details the recent FDA approval of ruxolitinib cream for vitiligo and how the accessibility of the topical therapy could help the roughly one million patients in the US who can't access standard treatment.
This episode of DocTalk features 5 expert retina specialists discussing the top line data from the conference.
Dr. Remo Panaccione speaks on promising long-term data of ustekinumab for Crohn's disease and ulcerative colitis, and how it could function as either a first-line treatment or alternative option for patients who were previously exposed biologic therapies.
Several prominent dermatologists sound off on the implications of this decision, JAK inhibitors, and how this approval will aid providers in redefining alopecia areata as an autoimmune disorder rather than simply a cosmetic condition.
Dr. Aric Prather discusses the pandemic, his research, and his presentation from SLEEP 2022 "Sleep in the Time of COVID: An Update on How Sleep Affects the Immune System".
Dr. Karan Lal returns to discuss key identifiers of pediatric morphea, and how dermatologists can collaborate with doctors from different branches of medicine to treat the disease.
Dr. Brown and Mr. Zavodnick speak on the first and only FDA-approved steroid-free topical medication in its class approved for psoriasis, and the data that bolstered this approval.
New research has suggested that approximately 2%-5% of patients with sarcoidosis also struggle with cardiac sarcoidosis.
Dr. Tara Vijayan speaks on improving COVID-19 treatment from “an equity standpoint, an ethical standpoint, and an evidence standpoint”.
Massachusetts General Hospital surgery resident Selena S. Li, MD, discusses her overseas volunteer work caring for refugees escaping their home during the Russia invasion.
Dr. Christine Rauscher details immunotherapy for seasonal allergies, which affect roughly 20 millions adults in the US
The Elevatum trial will assess the newly approved ophthalmic drug in patients from African American, Hispanic, Latin American, and Indigenous communities.
Dr. McKinley-Grant details the new health movement that aims to stop the cycle of suffering for people of color living with psoriatic disease.
Dr. Miriam Vos details the TARGET-NASH study, which indicated a higher prevalence of NAFLD in pediatric patients than previously thought.
Dr. Stephanie Lovinsky-Desir speaks on the staggering new data from the 23rd annual "State of the Air" report by the American Lung Association.
Dr. Sarah Asch details therapeutic strategies for treating pediatric patients with vitiligo.
Dr. Ruth Benca details the newest findings from the Wake Up America: The Night & Day Impact of Insomnia survey.
Dr. Karan Lal offers insights into diagnosing various forms of rosacea as well as common treatment methods.
Dr. Rees spoke of how addressing issues of representation could improve upon disparities in health care not only in the pediatric space but across all fields.
Dr. Karan Lal speaks to how he has used Instagram to host a variety of conversations regarding dermatology care and connect with patients who might not always have all the appropriate resources.
A new post-hoc analyses for the sodium oxybate FT218 found that the therapy improved daytime sleepiness, sleep quality, and refreshing nature of sleep in patients with narcolepsy.
Policy expert, Cindy Steinberg, of the US Pain Foundation explains the updated changes that have been proposed by the CDC to the Clinical Guideline for Prescribing Opioids.